프럭토올리고당(FOS) 관련 만성 변비
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.일부 연구에서 배변 횟수 증가를 보였습니다. 비피더스 생성 효과는 잘 확립되어 있으나 임상적 완하 효과는 이눌린보다 완만합니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dfructooligosaccharides\u0026condition\u003Dconstipation';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
일부 연구에서 배변 횟수 증가를 보였습니다. 비피더스 생성 효과는 잘 확립되어 있으나 임상적 완하 효과는 이눌린보다 완만합니다.
Key Study Findings
Review
Prebiotics and Gut Health: Mechanisms, Clinical Evidence, and Future Directions.
Dose: None
vs: None
Outcome: gut health outcomes including microbiota modulation and SCFA …
효과: None
None
대상 집단: healthy individuals, children, elderly, and those with constipation, metabolic syndrome, or dysbiosis
Randomized Controlled Trial
n=67
4 weeks
Double-blind
Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with …
Dose: None
vs: Placebo
Outcome: Weekly spontaneous bowel movements
효과: 4.94 vs 3.00 (P<0.001)
P<0.001
대상 집단: Older adults >=60 with functional constipation (Rome IV)
Other
Maternal or post-weaning dietary fructo-oligosaccharide supplementation reduces stillbirth rate of sows and diarrhea of weaned …
Dose: 2 g
vs: None
Outcome: Constipation symptoms
효과: None
P < 0.05
대상 집단: Constipation patients
Randomized Controlled Trial
Double-blind
Xylo-oligosaccharides improve functional constipation by targeted enrichment of Bifidobacterium.
Dose: 6 g
vs: Placebo
Outcome: Constipation symptoms
효과: None
None
대상 집단: Constipation patients
Systematic Review
Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Dose: None
vs: None
Outcome: Constipation symptoms
효과: OR: 10.36
p < 0.00001
대상 집단: Constipation patients
Randomized Controlled Trial
Double-blind
Advice to People with Parkinson's in My Clinic: Probiotics and Prebiotics.
Dose: None
vs: Placebo
Outcome: Constipation symptoms
효과: None
None
대상 집단: Constipation patients
Key Statistics
4
연구
350
참여자
↑
Positive
C
등급
Referenced Papers
Nutrients
2026
1 인용
The journal of …
2025
Xylo-oligosaccharides improve functional constipation by targeted enrichment of Bifidobacterium.
Other
Food science & …
2024
17 인용
Foods (Basel, Switzerland)
2024
8 인용
Journal of Parkinson's …
2024
4 인용
Animal nutrition (Zhongguo …
2024
4 인용
Carbohydrate polymers
2022
77 인용
Frontiers in nutrition
2022
22 인용
Nutrients
2019
35 인용
Nutrients
2018
30 인용
Journal of the …
2017
447 인용
Neurogastroenterology and motility
2017
131 인용
Nutrients
2017
28 인용
Clinical nutrition (Edinburgh, …
2017
20 인용
Peritoneal dialysis international …
2016
38 인용
World journal of …
2014
16 인용
Clinical nutrition (Edinburgh, …
2013
Nutrition (Burbank, Los …
2011
65 인용
Journal of medicinal …
2011
24 인용
Journal of physiology …
2009
312 인용
Journal of the …
2007
84 인용
BioFactors (Oxford, England)
2004
48 인용
The British journal …
2003
97 인용
Journal of renal …
1998
71 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 2-10 g/day
- prebioticeffect:
- 5-8 g/day for bifidogenic effect
- constipationsupport:
- 5-10 g/day
상한량: Well-tolerated up to 20 g/day; start low to avoid excess gas
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 4 weeks | Positive | 67 |
| 2 g | -- | Neutral | -- |
| 6 g | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
권장 복용 시간: With meals; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day)
- ⚠ Abdominal cramping at higher doses
- ⚠ May worsen IBS symptoms in FODMAP-sensitive individuals
- ⚠ Loose stools at excessive doses
알려진 상호작용
- ● Other FODMAPs (cumulative fermentation effect in sensitive individuals)
- ● Blood sugar-lowering medications (FOS may modestly affect glycemic response)
- ● Calcium supplements (FOS may enhance calcium absorption)
일일 최대 섭취 허용량: Well-tolerated up to 20 g/day; start low to avoid excess gas
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 프럭토올리고당(FOS) help with 만성 변비?
Based on 4 studies with 350 participants, there is limited but promising evidence that 프럭토올리고당(FOS) may support 만성 변비 management. Our evidence grade is C (Some Evidence).
How much 프럭토올리고당(FOS) should I take for 만성 변비?
Studies have used various dosages. A commonly studied range is 2-10 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 프럭토올리고당(FOS)?
Reported side effects may include Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day), Abdominal cramping at higher doses, May worsen IBS symptoms in FODMAP-sensitive individuals, Loose stools at excessive doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 프럭토올리고당(FOS) and 만성 변비?
We rate the evidence as Grade C (Some Evidence). This rating is based on 4 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 만성 변비
프럭토올리고당(FOS) 다른 건강 상태에 대한 근거
References
- [1] Cinara Regina A V Monteiro et al.. Nutrients. 2026. Prebiotics and Gut Health: Mechanisms, Clinical Evidence, and Future Directions. doi:10.3390/nu18030372 PubMed
- [2] Meina Li et al.. J Nutr Health Aging. 2025. Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with Functional Constipation: A Randomized, Double-Blind, … doi:10.1016/j.jnha.2025.100598 PubMed
- [3] Wanya Yi et al.. Food Sci Nutr. 2024. Xylo-oligosaccharides improve functional constipation by targeted enrichment of Bifidobacterium. doi:10.1002/fsn3.3827 PubMed
- [4] Hongmin Zhen et al.. Foods. 2024. Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. doi:10.3390/foods13243993 PubMed
- [5] Jia Wei Hor et al.. J Parkinsons Dis. 2024. Advice to People with Parkinson's in My Clinic: Probiotics and Prebiotics. doi:10.3233/JPD-240172 PubMed
- [6] Kaidi Ma et al.. Anim Nutr. 2024. Maternal or post-weaning dietary fructo-oligosaccharide supplementation reduces stillbirth rate of sows and diarrhea of weaned piglets. doi:10.1016/j.aninu.2024.04.002 PubMed
- [7] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
- [8] Qi Zhang et al.. Front Nutr. 2022. In vitro Study of Bifidobacterium lactis BL-99 With Fructooligosaccharide Synbiotics Effected on the Intestinal Microbiota. doi:10.3389/fnut.2022.890316 PubMed
- [9] Jan de Vries et al.. Nutrients. 2019. Effects of β-Fructans Fiber on Bowel Function: A Systematic Review and Meta-Analysis. doi:10.3390/nu11010091 PubMed
- [10] Daniela da Silva Souza et al.. Nutrients. 2018. Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial Assessing the Effect of Fructooligosaccharides in Infants with Constipation. doi:10.3390/nu10111602 PubMed
- [11] Johnson W McRorie et al.. J Acad Nutr Diet. 2017. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and … doi:10.1016/j.jand.2016.09.021 PubMed
- [12] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
- [13] Shinji Jinno et al.. Nutrients. 2017. Maternal Prebiotic Ingestion Increased the Number of Fecal Bifidobacteria in Pregnant Women but Not in Their Neonates Aged One Month. doi:10.3390/nu9030196 PubMed
- [14] Annelisa Silva E Alves de Carvalho Santos et al.. Clin Nutr. 2017. Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: Randomized clinical trial. doi:10.1016/j.clnu.2016.06.005 PubMed
- [15] Kulwara Meksawan et al.. Perit Dial Int. 2016. Effects of Fructo-Oligosaccharide Supplementation on Constipation in Elderly Continuous Ambulatory Peritoneal Dialysis Patients. doi:10.3747/pdi.2014.00015 PubMed
- [16] Petra A M J Scholtens et al.. World J Gastroenterol. 2014. Stool characteristics of infants receiving short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides: a review. doi:10.3748/wjg.v20.i37.13446 PubMed
- [17] Dan L Waitzberg et al.. Clin Nutr. 2013. Effect of synbiotic in constipated adult women - a randomized, double-blind, placebo-controlled study of clinical response. doi:10.1016/j.clnu.2012.08.010 PubMed
- [18] Chi-Hua Yen et al.. Nutrition. 2011. Beneficial effects of fructo-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents--a placebo-controlled, diet-controlled trial. doi:10.1016/j.nut.2010.02.009 PubMed
- [19] Esther Nova et al.. J Med Food. 2011. Beneficial effects of a synbiotic supplement on self-perceived gastrointestinal well-being and immunoinflammatory status of healthy adults. doi:10.1089/jmf.2008.0328 PubMed
- [20] M Sabater-Molina et al.. J Physiol Biochem. 2009. Dietary fructooligosaccharides and potential benefits on health. doi:10.1007/BF03180584 PubMed
- [21] Syed H Tariq. J Am Med Dir Assoc. 2007. Constipation in long-term care. doi:10.1016/j.jamda.2007.02.009 PubMed
- [22] Takahisa Tokunaga. Biofactors. 2004. Novel physiological function of fructooligosaccharides. doi:10.1002/biof.552210117 PubMed
- [23] Nancy Moore et al.. Br J Nutr. 2003. Effects of fructo-oligosaccharide-supplemented infant cereal: a double-blind, randomized trial. doi:10.1079/bjn2003950 PubMed
- [24] D B Cockram et al.. J Ren Nutr. 1998. Safety and tolerance of medical nutritional products as sole sources of nutrition in people on hemodialysis. doi:10.1016/s1051-2276(98)90034-6 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.